Previous 10 | Next 10 |
Many analysts expect the stock market bull run to continue this year, backed by a V-shaped economic recovery. So, lesser-known companies such as Hologic Inc. (HOLX), PTC Inc. (PTC), and Par Technology Corp. (PAR) have the potential for manifold growth, offering better returns than popular gro...
Hologic has been a long-term play on women’s health. The company has seen a huge 2020 thanks and despite COVID-19. Current earnings are not sustainable, as the question is what the new normal profit rate would be. After a big move in 2020, shares look more than fully pr...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Hologic ([[HOLX]] +3.4%) moves up after the company released its Q1 prelim revenue estimate much above its guidance and market expectations.Healthcare equipment company says it expects Q1 total revenues of ~$1.61B (+89.3% Y/Y), compared to its most recent guidance range of $1.35-$1.43B, ...
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2021 on Wednesday, January 27, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. East...
– Revenue of $1,609.8 Million Grows 89.3%, 86.5% in Constant Currency – – Excluding Acquisitions and Divestitures, Organic Revenue More than Doubles – – Company Announces New $1.0 Billion Share Repurchase Authorization, Pays Off Revolving Debt ...
Despite a decline next year, COVID-19 testing-related tailwinds could increase in 2021, Wells Fargo points out, projecting vaccine and therapeutic Bioproduction to grow more sustainably than testing through 2023 and beyond.In its 2021outlook for the sector of Life Science Tools, Services, &am...
Hologic (HOLX) has agreed to acquire Biotheranostics, a privately held, commercial-stage company that provides molecular diagnostic tests for breast and metastatic cancers, for ~$230M.Biotheranostics generated ~$33M of revenue in calendar 2020. The acquisition is expected to be slightly ...
– Transaction Accelerates Hologic’s Entry into Oncology Growth Market, Provides New Lab Capabilities – – Hologic’s Commercial Resources, Expertise in Molecular Automation Expected to Boost Biotheranostics Growth – Hologic, Inc. (Nasd...
Hologic (HOLX) has completed the acquisition of SOMATEX Medical Technologies for ~$64M. As a result of the acquisition, Hologic will also enhance its sales presence in Europe by expanding its direct channel in Germany and its network of regional and international distributor partners. SOMATEX...
News, Short Squeeze, Breakout and More Instantly...
2024-07-30 10:30:04 ET BTIG analyst issues NEUTRAL recommendation for HOLX on July 30, 2024 08:28AM ET. The previous analyst recommendation was Neutral. HOLX was trading at $79.64 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current an...
2024-07-30 09:30:03 ET RBC Capital analyst issues SECTOR PERFORM recommendation for HOLX on July 30, 2024 07:43AM ET. The previous analyst recommendation was Sector Perform. HOLX was trading at $79.64 at issue of the analyst recommendation. The overall analyst consensus ...
– Revenue of $1,011.4 Million, GAAP Diluted EPS of $0.82, and Non-GAAP Diluted EPS of $1.06; All Met or Exceeded Guidance – – Total Company Revenue Growth of 2.7%, or 3.1% in Constant Currency and 5.8% Organically excluding COVID-19; Against Growth of 18.4% in the Prior Y...